Newsfeeds - Spark Newswire

3 minute read

European Medicines Agency Validates Marketing Authorization Application For Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer

Today, 10:03 PM

– Application Based on Statistically Significant and Clinically Meaningful Overall Survival and Progression-Free Survival Results from the Phase 3 TROPiCS-02 Study – – Supplemental Biologics License

GILD

1 minute read

RBC Capital Downgrades Gilead Sciences to Sector Perform, Announces $87 Price Target

By Benzinga Newsdesk

Today, 10:03 PM

RBC Capital analyst Brian Abrahams downgrades Gilead Sciences (NASDAQ:GILD) from Outperform to Sector Perform and announces $87 price target.

GILD

4 minute read

FTX Exchange’s Assets Worth $3.5B Held By Bahamian Regulators, Italy PM To Meet Intel Over Chip Investment, New Oral COVID Antiviral Might Be Better Than Pfizer’s Paxlovid: Today’s Top Stories

By Vandana Singh

Today, 10:03 PM

Reuters

$BNB

1 minute read

New Oral COVID-19 Antiviral Might Be Better Than Pfizer’s Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows

By Vandana Singh

Today, 10:03 PM

A study in China shows that a remdesivir analog, dubbed VV116, is as effective as Pfizer Inc's (NYSE: PFE) oral COVID-19 pill.

GILD

1 minute read

Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program

By Vandana Singh

Today, 10:03 PM

Gilead Sciences Inc (NASDAQ:GILD) and Jounce Therapeutics Inc (NASDAQ:JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to…

GILD

2 minute read

Markets
News

Tesla, Apple, Lightjump, Southwest, Gilead: Why These 5 Stocks Are Drawing Investors’ Attention Today

By Bhavik Nair

Today, 10:03 PM

U.S. markets opened lower on Tuesday in a truncated week after rising bond yields dragged major growth stocks and indices.

AAPL

5 minute read

Biogen’s 2nd Alzheimer’s Antibody, BeiGene’s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors

By Shanthi Rexaline

Today, 10:03 PM

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

BGNE

1 minute read

Gilead Enables Easier Veklury Access Through Retail And Specialty Pharmacies For Long-Term Care And Skilled Nursing Facilities

By Benzinga Newsdesk

Today, 10:03 PM

- Reuters

GILD

1 minute read

FDA Approves Gilead’s New HIV Treatment For Heavily Treated With Multi-Drug Resistant Patients

By Vandana Singh

Today, 10:03 PM

The FDA has approved Gilead Sciences Inc’s (NASDAQ:GILD) Sunlenca (lenacapavir), in combination with another antiretroviral (s) (ARV), for HIV-1 infection in…

GILD

8 minute read

Sunlenca Receives FDA Approval As A First-In-Class, Twice-Yearly Treatment Option For People Living With Multi-Drug Resistant HIV

By Benzinga Newsdesk

Today, 10:03 PM

– Sunlenca is the First and Only Approved Capsid Inhibitor-Based HIV Treatment Option – – New Drug Application Approval Based on High Rates of Sustained Virologic Suppression in the

GILD